Lisette Stork‐Sloots

906 total citations
49 papers, 633 citations indexed

About

Lisette Stork‐Sloots is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lisette Stork‐Sloots has authored 49 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cancer Research, 29 papers in Oncology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Lisette Stork‐Sloots's work include Breast Cancer Treatment Studies (34 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Genomics and Diagnostics (13 papers). Lisette Stork‐Sloots is often cited by papers focused on Breast Cancer Treatment Studies (34 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Genomics and Diagnostics (13 papers). Lisette Stork‐Sloots collaborates with scholars based in United States, Netherlands and Italy. Lisette Stork‐Sloots's co-authors include Femke De Snoo, Femke A. de Snoo, Stefan Glück, Justine Peeters, George Somlo, Pat W. Whitworth, James Pellicane, Peter D. Beitsch, J. David Beatty and Ramón Salazar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Lisette Stork‐Sloots

48 papers receiving 613 citations

Peers

Countries citing papers authored by Lisette Stork‐Sloots

Since Specialization

Citations

This map shows the geographic impact of Lisette Stork‐Sloots's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisette Stork‐Sloots with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisette Stork‐Sloots more than expected).

Fields of papers citing papers by Lisette Stork‐Sloots

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisette Stork‐Sloots. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisette Stork‐Sloots. The network helps show where Lisette Stork‐Sloots may publish in the future.

Co-authorship network of co-authors of Lisette Stork‐Sloots

This figure shows the co-authorship network connecting the top 25 collaborators of Lisette Stork‐Sloots. A scholar is included among the top collaborators of Lisette Stork‐Sloots based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisette Stork‐Sloots. Lisette Stork‐Sloots is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) 2022 ·Cancer Research ·Massimo Cristofanilli, (unknown), (unknown), Hallgeir Rui, Marek Doležal, Lisette Stork‐Sloots, Femke De Snoo, Christopher Recknor, Vandana G. Abramson	6
2	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial 2021 ·SHILAP Revista de lepidopterología ·Noa Biran, Binod Dhakal, Suzanne Lentzsch, David S. Siegel, Saad Z. Usmani, Adriana Rossi, Cara A. Rosenbaum, Divaya Bhutani, David H. Vesole, Cesar Rodriguez, Ajay K. Nooka, Frits van Rhee, Lisette Stork‐Sloots, Femke De Snoo, Pritish K. Bhattacharyya, Durga Prasad Dash, (unknown), Martin H. van Vliet, Parameswaran Hari, Rubén Niesvizky	9
3	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS). 2019 ·Journal of Clinical Oncology ·Parameswaran Hari, Suzanne Lentzsch, David S. Siegel, Saad Z. Usmani, Binod Dhakal, Adriana Rossi, Cara A. Rosenbaum, Siyang Leng, Divaya Bhutani, Noa Biran, David H. Vesole, Manisha Bhutani, Lisette Stork‐Sloots, Femke De Snoo, (unknown), M. van Vliet, Rubén Niesvizky	2
4	Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) 2017 ·Annals of Surgical Oncology ·Peter D. Beitsch, Pat W. Whitworth, Paul L. Baron, (unknown), (unknown), Paul Richards, Mary K. Murray, James Pellicane, (unknown), (unknown), Lisette Stork‐Sloots, Femke De Snoo, (unknown), Laura A. Lee	28
5	Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial 2017 ·Breast Cancer Research and Treatment ·(unknown), Giuseppe Viale, Femke A. de Snoo, Leen Slaets, (unknown), Laura van ‘t Veer, Emiel J. Rutgers, Martine Piccart, Lisette Stork‐Sloots, Annuska M. Glas, Luca Russo, Patrizia Dell’Orto, (unknown), Saskia Litière, Fátima Cardoso	45
6	An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer 2016 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Jelle Wesseling, Corrado Tinterri, Anna Sapino, Fabrizio Zanconati, (unknown), Bichlien Nguyen, Kenneth Deck, Patrizia Querzoli, Tiziana Perin, C Giardina, Gerhard Seitz, J M Guinebretière, (unknown), (unknown), Femke De Snoo, Lisette Stork‐Sloots, Paul Roepman, Toru Watanabe, P. Cusumano	10
7	Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping 2016 ·Annals of Surgical Oncology ·Pat W. Whitworth, Peter D. Beitsch, (unknown), James Pellicane, (unknown), Mary K. Murray, Laura A. Lee, (unknown), (unknown), Paul L. Baron, Lisette Stork‐Sloots, Femke A. de Snoo, J. David Beatty	63
8	Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer 2016 ·Breast Cancer Research and Treatment ·Giuseppe Viale, Leen Slaets, Femke A. de Snoo, Jan Bogaerts, Leila Russo, Laura van’t Veer, Emiel J. Rutgers, Martine Piccart, Lisette Stork‐Sloots, Patrizia Dell’Orto, Annuska M. Glas, Fátima Cardoso	16
9	Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups 2015 ·Breast Cancer Research and Treatment ·Katharine Yao, Robert Goldschmidt, (unknown), Jelle Wesseling, Lisette Stork‐Sloots, Femke De Snoo, Massimo Cristofanilli	17
10	Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients 2015 ·Breast Care ·Hideo Shimizu, Yoshiya Horimoto, Atsushi Arakawa, Hiroshi Sonoue, (unknown), (unknown), Katsuya Nakai, (unknown), Emi Tokuda, Yuka Takahashi, (unknown), (unknown), (unknown), (unknown), Lisette Stork‐Sloots, Femke De Snoo, Mitsue Saito	5
11	Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy 2015 ·Annals of Surgical Oncology ·Paul L. Baron, Peter D. Beitsch, Danielle Boselli, James T. Symanowski, James Pellicane, J. David Beatty, Paul Richards, (unknown), (unknown), Laura A. Lee, Mary K. Murray, Femke A. de Snoo, Lisette Stork‐Sloots, Mark Gittleman, Stephanie Akbari, Pat W. Whitworth	24
12	Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy 2014 ·Medical Oncology ·Soley Bayraktar, Melanie Royce, Lisette Stork‐Sloots, Femke De Snoo, Stefan Glück	14
13	High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial 2014 ·Annals of Oncology ·Giulia Viale, Leen Slaets, Jan Bogaerts, Emiel J. Rutgers, Laura van’t Veer, Martine Piccart, Femke A. de Snoo, Lisette Stork‐Sloots, Luca Russo, Patrizia Dell’Orto, Jeroen van den Akker, Annuska M. Glas, Fátima Cardoso	45
14	European inter-institutional impact study of MammaPrint 2014 ·The Breast ·P. Cusumano, Daniele Generali, Eva Ciruelos, Luís Manso, Ismael Ghanem, Éric Lifrange, Guy Jérusalem, Joost M. Klaase, Femke De Snoo, Lisette Stork‐Sloots, (unknown), (unknown)	18
15	Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) 2014 ·Annals of Surgical Oncology ·Pat W. Whitworth, Lisette Stork‐Sloots, Femke A. de Snoo, Paul Richards, (unknown), J. David Beatty, (unknown), James Pellicane, Bichlien Nguyen, Laura Lee, (unknown), Mark Gittleman, Stephanie Akbari, Peter D. Beitsch	52
16	Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy 2013 ·Breast Cancer Research and Treatment ·Stefan Glück, Femke De Snoo, Justine Peeters, Lisette Stork‐Sloots, George Somlo	76
17	Abstract P6-06-02: Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer 2013 ·Cancer Research ·(unknown), Linda C. Clark, (unknown), Natasha Howard, Jeff King, Géza Ács, (unknown), (unknown), (unknown), Lisette Stork‐Sloots, Femke De Snoo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	8
18	Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients 2012 ·Annals of Surgical Oncology ·Bichlien Nguyen, P. Cusumano, Kenneth Deck, (unknown), Agustin A. García, (unknown), Edgardo Rivera, Katharine Yao, Femke A. de Snoo, Jeroen van den Akker, Lisette Stork‐Sloots, Daniele Generali	30
19	Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. 2012 ·Journal of Clinical Oncology ·Giuseppe Viale, Leen Slaets, Femke De Snoo, Laura van ‘t Veer, Emiel J. Rutgers, Jan Bogaerts, Lisette Stork‐Sloots, (unknown), Leila Russo, Patrizia Dell’Orto, Fátima Cardoso, Martine Piccart	1
20	Comparison of histopathological and gene expression-based typing of cancer of unknown primary 2009 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Lars Morawietz, Arno Floore, Lisette Stork‐Sloots, Gunnar Folprecht, Reinhard Buettner, Anja Rieger, Manfred Dietel, (unknown)	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact